Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models.

ABSTRACT: YSCH-01, a recombinant L-IFN oncolytic adenovirus based anticancer drug with dual anti-tumor effects, has displayed significant antitumor properties in cancer treatment. However, its specific role in osteosarcoma and the underlying mechanisms remain under studied. Therefore, we analyzed clinical samples and performed experiments using osteosarcoma cell lines in both in vitro and in vivo settings. At the RNA and protein levels, the expression of L-IFN gene carried by YSCH-01 showed the potential antitumor properties. RNA-seq analysis of tumor samples treated with YSCH-01 provided insights into the altered gene expression profiles and signaling pathways, shedding light on the molecular basis of its antitumor effects. Those findings demonstrated that YSCH-01 displayed dose-dependent infectivi

SUBMITTER: Jin H 

PROVIDER: S-EPMC12695983 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature